Kinase activity of mutant LRRK2 mediates neuronal toxicity

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Nature Neuroscience

• Publication date

  2006-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nn1776PMID 16980962
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain.

  2006cited by this paper
• Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.

  2006cited by this paper
• The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.

  2006cited by this paper
• A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease.

  2005cited by this paper
• LRRK2 mutations in Parkinson disease

  2005cited by this paper
• Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.

  2005cited by this paper
• Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.

  2005cited by this paper
• A common LRRK2 mutation in idiopathic Parkinson's disease.

  2005cited by this paper
• Genetics of Parkinson's disease

  2005cited by this paper
• LRRK2 mutations and Parkinsonism.

  2005cited by this paper
• Genetics of Parkinson's disease

  2005cited by this paper
• Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

  2004cited by this paper
• Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

  2004cited by this paper
• Identification of residues in the human guanylate-binding protein 1 critical for nucleotide binding and cooperative GTP hydrolysis.

  2004cited by this paper
• Roc, a Ras/GTPase domain in complex proteins.

  2003cited by this paper
• Nature Neuroscience

  year unknowncited by this paper

• LRRK2 regulates ArfGAP1 membrane localization, activity and neuronal toxicity via phosphorylation within its lipid-sensing ALPS2 motif

  2026cites this paper
• Regulation between LRRK2 and PP2A signaling in cellular models of Parkinson’s disease

  2026cites this paper
• Pathogenesis of Parkinson's Disease.

  2025cites this paper
• Targeting protein kinases in Parkinson’s disease: the emerging role of phytoconstituents

  2025cites this paper
• LRRK2 kinase activity restricts NRF2-dependent mitochondrial protection in microglia

  2025cites this paper
• RNA sequence analysis of somatic mutations in aging and Parkinson’s Disease

  2025cites this paper
• Beyond Clathrin: Decoding the Mechanism of Ultrafast Endocytosis.

  2025cites this paper
• LRRK2 interactions with microtubules are independent of LRRK2-mediated Rab phosphorylation

  2025cites this paper
• LRRK2 Mediates α-Synuclein-Induced Neuroinflammation and Ferroptosis through the p62-Keap1-Nrf2 Pathway in Parkinson’s Disease

  2025cites this paper
• Association between LRRK2 gene polymorphisms and Parkinson’s disease progression in a Chinese Han population

  2025cites this paper
• LRRK2 kinase-mediated accumulation of lysosome-associated phospho-Rabs in tauopathies and synucleinopathies

  2025cites this paper
• Micro-and mesoscale aspects of neurodegeneration in engineered human neural networks carrying the LRRK2 G2019S mutation

  2024cites this paper
• LRRK2 kinase activity restricts NRF2-dependent mitochondrial protection in microglia

  2024cites this paper
• Key genes and convergent pathogenic mechanisms in Parkinson disease

  2024cites this paper
• Experimental models of Parkinson's disease: Challenges and Opportunities.

  2024cites this paper
• Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to date

  2024cites this paper
• 14-3-3 phosphorylation inhibits 14-3-3θ's ability to regulate LRRK2 kinase activity and toxicity.

  2024cites this paper
• Pharmacological Inhibition of LRRK2 Exhibits Neuroprotective Activity in Mouse Photothrombotic Stroke Model

  2024cites this paper
• Parkinson disease therapy: current strategies and future research priorities

  2024cites this paper
• CalDAG-GEFI acts as a guanine nucleotide exchange factor for LRRK2 to regulate LRRK2 function and neurodegeneration

  2024cites this paper
• Parkinson's disease – genetic cause

  2023cites this paper
• The role of medial prefrontal cortex in cognition, aging and Parkinson disease

  2023cites this paper
• Parkinson ' s disease : phenotype and pathology of the prototypic disease

  2023cites this paper
• LRRK2 Attenuates Antioxidant Response in Familial Parkinson’s Disease Derived Neural Stem Cells

  2023cites this paper
• Nrf2 Expression Is Decreased in LRRK2 Transgenic Mouse Brain and LRRK2 Overexpressing SH-SY5Y Cells.

  2023cites this paper
• Role of neuroinflammation in neurodegeneration development

  2023cites this paper
• 14-3-3 phosphorylation inhibits 14-3-3θ’s ability to regulate LRRK2 kinase activity

  2023cites this paper
• A primate nigrostriatal atlas of neuronal vulnerability and resilience in a model of Parkinson’s disease

  2023influential citation
• Regulation of LRRK2 mRNA stability by ATIC and its substrate AICAR through ARE‐mediated mRNA decay in Parkinson's disease

  2023cites this paper
• Imaging Leucine-Rich Repeat Kinase 2 In Vivo with 18F-Labeled Positron Emission Tomography Ligand.

  2022cites this paper
• High-content phenotyping of Parkinson's disease patient stem cell-derived midbrain dopaminergic neurons using machine learning classification

  2022cites this paper
• The role of tyrosine hydroxylase–dopamine pathway in Parkinson’s disease pathogenesis

  2022cites this paper
• Autophagy and Its Association with Genetic Mutations in Parkinson Disease

  2022cites this paper
• LRRK2 deficiency mitigates colitis progression by favoring resolution of inflammation and restoring homeostasis of gut microbiota.

  2022cites this paper
• Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice

  2022cites this paper
• Parkinson's disease: The prevalence of the LRRK2-G2019S mutation among the population of the South-West of Morocco

  2022cites this paper
• LRRK2 and Proteostasis in Parkinson’s Disease

  2022cites this paper
• Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity

  2022cites this paper
• Machine learning-aided multidimensional phenotyping of Parkinson’s disease patient stem cell-derived midbrain dopaminergic neurons

  2022cites this paper
• A step forward for LRRK2 inhibitors in Parkinson’s disease

  2022cites this paper
• Inflammation and immune dysfunction in Parkinson disease

  2022cites this paper
• LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease

  2022cites this paper
• The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders

  2022influential citation
• Targeting LRRK2 in Parkinson’s disease

  2022cites this paper
• High-Throughput Sequencing Haplotype Analysis Indicates in LRRK2 Gene a Potential Risk Factor for Endemic Parkinsonism in Southeastern Moravia, Czech Republic

  2022cites this paper
• Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling of Familial Parkinson’s Disease

  2022cites this paper
• The Genetics of Parkinson’s Disease

  2021cites this paper
• LRRK2 coding variants and the risk of Parkinson's disease

  2021cites this paper
• Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes.

  2021cites this paper
• Mutant TMEM230 induced neurodegeneration and impaired axonal mitochondrial transport.

  2021cites this paper
• LRRK2 at the Crossroad of Aging and Parkinson’s Disease

  2021cites this paper
• 14-3-3 Proteins: Novel Pharmacological Targets in Neurodegenerative Diseases.

  2021cites this paper
• A LRRK2 GTP Binding Inhibitor, 68, Reduces LPS-Induced Signaling Events and TNF-α Release in Human Lymphoblasts

  2021cites this paper
• LRRK2 signaling in neurodegeneration: two decades of progress.

  2021cites this paper
• Parkinson’s Disease as a Risk Factor for Melanoma: A Review

  2021cites this paper
• An MRI study: Mutant G2019S-LRRK2 induces abnormalities in arteriolar cerebral blood volume in mouse brains

  2021cites this paper
• In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity.

  2021cites this paper
• Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson’s Disease

  2021cites this paper
• Dysregulated mRNA Translation in the G2019S LRRK2 and LRRK2 Knock-Out Mouse Brains

  2021cites this paper
• The cell biology of Parkinson’s disease

  2021cites this paper
• Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection

  2021cites this paper
• The NRF2-Dependent Transcriptional Regulation of Antioxidant Defense Pathways: Relevance for Cell Type-Specific Vulnerability to Neurodegeneration and Therapeutic Intervention

  2021cites this paper
• Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk

  2021cites this paper
• Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.

  2021cites this paper
• Neurobiology: A pathogenic tug of war

  2021cites this paper
• Matrix Metalloproteinase-8 Inhibitor Ameliorates Inflammatory Responses and Behavioral Deficits in LRRK2 G2019S Parkinson’s Disease Model Mice

  2021cites this paper
• Dysregulation of the AP2M1 phosphorylation cycle by LRRK2 impairs endocytosis and leads to dopaminergic neurodegeneration

  2021cites this paper
• Modelling the functional genomics of Parkinson’s disease in Caenorhabditis elegans: LRRK2 and beyond

  2021cites this paper
• Modelling the Functional Genomics of Parkinson’s in Caenorhabditis elegans: LRRK2 and Beyond

  2021cites this paper
• The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo

  2021cites this paper
• Dysregulated Interorganellar Crosstalk of Mitochondria in the Pathogenesis of Parkinson’s Disease

  2020cites this paper
• Action mechanism of Roman chamomile in the treatment of anxiety disorder based on network pharmacology.

  2020cites this paper
• Mutant G2019S-LRRK2 Induces Abnormalities in Arteriolar Cerebral Blood Volume in Mouse Brains: An MRI Study.

  2020cites this paper
• Leucine-rich repeat kinase 2 (LRRK2) and Parkinson's disease: from genetics to pathobiology

  2020cites this paper
• LRRK2 Inhibition Ameliorates Dexamethasone-Induced Glucose Intolerance via Prevents Impairment in GLUT4 Membrane Translocation in Adipocytes.

  2020cites this paper
• The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.

  2020cites this paper
• Novel Cell-Based Assay for Identification of LRRK2 Inhibitors Using Its Aberrant Regulation of a Pluripotency Gene

  2020cites this paper
• Advancement in the modelling and therapeutics of Parkinson's disease.

  2020cites this paper
• Pathological Functions of LRRK2 in Parkinson’s Disease

  2020cites this paper
• RAB7L1 Participates in Secondary Brain Injury Induced by Experimental Intracerebral Hemorrhage in Rats

  2020cites this paper
• Distinct Roles for RAB10 and RAB29 in Pathogenic LRRK2-Mediated Endolysosomal Trafficking Alterations

  2020cites this paper
• Genetics of Parkinson's disease

  2020cites this paper
• Defects in mRNA Translation in LRRK2-Mutant hiPSC-Derived Dopaminergic Neurons Lead to Dysregulated Calcium Homeostasis.

  2020cites this paper
• The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson’s Disease

  2020cites this paper
• LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease?

  2020cites this paper
• LRRK2 regulates AP2M1 phosphorylation cycles to mediate endocytosis and dopaminergic neurodegeneration

  2020cites this paper
• Midbrain Organoids: A New Tool to Investigate Parkinson’s Disease

  2020cites this paper
• Combined Knockout of Lrrk2 and Rab29 Does Not Result in Behavioral Abnormalities in vivo

  2020cites this paper
• Fluctuation Imaging of LRRK2 Reveals that the G2019S Mutation Alters Spatial and Membrane Dynamics

  2020cites this paper
• LRRK2-Related Parkinson’s Disease Due to Altered Endolysosomal Biology With Variable Lewy Body Pathology: A Hypothesis

  2020cites this paper
• LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson’s

  2020cites this paper
• Small GTPases of the Ras and Rho Families Switch on/off Signaling Pathways in Neurodegenerative Diseases

  2020cites this paper
• Structural and functional alterations associated with the LRRK2 G2019S mutation revealed in structured human neural networks

  2020influential citation
• Expression analysis of genes involved in mitochondrial biogenesis in mice with MPTP-induced model of Parkinson's disease

  2020cites this paper
• Endosomal sorting pathways in the pathogenesis of Parkinson's disease.

  2020cites this paper
• Origins of Parkinson’s Disease in Brain Development: Insights From Early and Persistent Effects of LRRK2-G2019S on Striatal Circuits

  2020cites this paper
• The multi‐faceted role of mitochondria in the pathology of Parkinson’s disease

  2020cites this paper
• Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease

  2020cites this paper
• LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits

  2020cites this paper
• LRRK2 and Rab10 Coordinate Macropinocytosis to Mediate Immunological Responses in Phagocytes

  2020cites this paper